VA's $1.18B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for FY2026

Contract Overview

Contract Amount: $1,184,200,532 ($1.2B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-10-01

End Date: 2025-10-31

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER

Plain-Language Summary

Department of Veterans Affairs obligated $1.18 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER Key points: 1. Significant contract value of over $1.18 billion highlights the scale of pharmaceutical procurement. 2. McKesson Corporation, a major player, secures a substantial portion of VA's pharmaceutical needs. 3. Potential risks include supply chain disruptions and price fluctuations in the pharmaceutical market. 4. This contract falls within the Healthcare sector, crucial for veteran medical services.

Value Assessment

Rating: good

The $1.18 billion value for a single year of pharmaceutical prime vendor services appears competitive given the scale and essential nature of the contract. Benchmarking against similar large-scale federal pharmaceutical contracts would provide a more precise assessment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: unknown

The competition method is not specified, but large pharmaceutical prime vendor contracts often involve complex bidding processes. The impact on price discovery depends heavily on the rigor of the solicitation and evaluation criteria.

Taxpayer Impact: The VA's ability to secure necessary pharmaceuticals at competitive prices directly impacts taxpayer funds allocated to veteran healthcare.

Public Impact

Ensures a steady supply of essential medications for veterans nationwide. Supports the operational readiness of VA healthcare facilities. Potential for cost savings through bulk purchasing and efficient distribution.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Lack of transparency on competition method.
  • Potential for single-source reliance if competition is limited.
  • Vulnerability to pharmaceutical price inflation.

Positive Signals

  • Addresses critical need for pharmaceutical supplies.
  • Leverages established vendor capabilities.
  • Supports a large veteran population.

Sector Analysis

The healthcare sector, particularly pharmaceutical procurement, is a significant area of federal spending. Benchmarks for prime vendor contracts can vary widely based on drug types, volume, and service requirements.

Small Business Impact

This contract is likely awarded to a large prime vendor, potentially limiting direct opportunities for small businesses in the prime role. However, subcontractors may include small businesses for logistics, distribution, or specialized services.

Oversight & Accountability

Oversight will be critical to ensure McKesson meets performance standards, maintains drug availability, and adheres to pricing agreements. The VA's contracting officers and quality assurance personnel will play key roles.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Potential for price increases due to market volatility.
  • Risk of supply chain disruptions impacting medication availability.
  • Dependence on a single large vendor.
  • Ensuring equitable access to medications across all VA facilities.

Tags

department-of-veterans-affairs, delivery-order, billion-dollar

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.18 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.18 billion.

What is the period of performance?

Start: 2025-10-01. End: 2025-10-31.

What specific metrics are used to evaluate McKesson's performance under this contract to ensure value for taxpayer dollars?

Performance evaluation likely includes metrics such as on-time delivery rates, order accuracy, drug availability, and adherence to contract pricing. The VA's contract requires detailed reporting on these aspects. Regular performance reviews and audits are essential to ensure McKesson meets its obligations and provides value, preventing potential cost overruns or service degradation.

What are the primary risks associated with relying on a single vendor for such a large volume of pharmaceuticals, and how are they mitigated?

The primary risks include supply chain disruptions, potential price gouging, and lack of competitive pressure. Mitigation strategies may involve contract clauses for contingency planning, price adjustment limitations, and robust inventory management. The VA likely has contingency plans in place to address potential vendor failures or significant supply chain interruptions.

How does this contract contribute to the overall effectiveness of the VA's healthcare system in serving veterans?

This contract is fundamental to the effectiveness of the VA's healthcare system by ensuring veterans have consistent access to necessary medications. Reliable pharmaceutical supply supports treatment continuity, improves health outcomes, and allows VA facilities to operate efficiently. The contract's success directly translates to the quality of care veterans receive.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending